Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1CheckMate -76K marks the fifth Opdivo-based indication in earlier stages of cancer, in the U.S.1Opdivo is the only PD-1 inhibitor that is indicated as an adjuvant treatment...
Talquetamab is a bispecific T-cell engaging antibody that binds to CD3 The Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that
Alex Hajduczok, MD, provides perspective on the new GUIDE-HF trial data presented at HFSA 2023.
1. In this randomized controlled trial, complete revascularization reduced the risk of myocardial infarction, stroke, or ischemia-driven revascularization at one year in patients with myocardial infarction compared to culprit lesion revascularization. 2. There was no difference in safety outcomes, including acute kidney injury, stroke, or bleeding, between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: The decision
1. In this randomized controlled trial, ferric carboxymaltose was not superior to placebo in improving death and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF) and concurrent iron deficiency. 2. Ferric carboxymaltose was safe and improved six-minute walk distance. Evidence Rating Level: 1 (Excellent) Study Rundown: Iron deficiency is a common complication